Figure 3. Biometric measurements in FDM, vehicle-FDM, and APO-FDM (0.025 to 250 ng/μl) groups before and at 11 days of FDM. A: Refraction; B: Vitreous length; C: Axial length. APO effectively blocked the development of FDM by inhibiting the excessive elongation of vitreous chamber in a dose-dependent pattern (* indicates a p<0.05 compared to the fellow eye, paired t-test).